Clinical Trial Update: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update comparing TAB014 to Lucentis for neovascular age-related macular degeneration; the study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)
• TAB014

Snippet

Sponsor: BioDlink Biopharm Co., Ltd. | Conditions: Neovascular Age-related Macular Degeneration | Phase 3 | Status: ACTIVE_NOT_RECRUITING